• Recently, MakeMyTrip completed a large upsized capital raise, issuing 18.4 million new ordinary shares at US$90 each alongside US$1.44 billion of 0.00% convertible senior notes due 2030, materially boosting its cash reserves but introducing the prospect of future equity dilution.
• Alongside fresh equity awards to senior leaders in the form of time- and performance-based restricted stock units, the capital injection tightens the link between management incentives, balance sheet capacity, and the company’s long-term growth plans.
• We’ll now examine how this sizeable equity and convertible notes issuance could reshape MakeMyTrip’s investment narrative and risk profile.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

MakeMyTrip Investment Narrative Recap

To own MakeMyTrip, you need to believe its online travel platform can keep deepening its hold on Indian and outbound demand despite competition and cyclical shocks. The recent US$1.44 billion zero coupon convertible notes and US$1.66 billion equity raise materially expand funding flexibility, which could support growth initiatives but also adds future dilution risk. In the near term, the key catalyst remains execution on travel demand recovery, while the biggest risk is pressure on margins from higher customer acquisition and promotion costs.

Among recent developments, the large equity and convertible notes issuance stands out, especially given MakeMyTrip’s history of buybacks and capital returns. This shift from share repurchases to significant capital raising may influence how you weigh future growth opportunities against dilution and negative equity on the balance sheet. How effectively management allocates this new cash will likely shape how you think about the sustainability of earnings after a year of weaker net profit margins.

Yet while the funding boost looks positive on the surface, the dilution risk and already high valuation multiples are something investors should be aware of...

MakeMyTrip's narrative projects $1.7 billion revenue and $277.9 million earnings by 2029.

Uncover how MakeMyTrip's forecasts yield a $70.73 fair value, a 21% upside to its current price.

Exploring Other Perspectives

The most cautious analysts were already assuming revenues of about US$1.8 billion and earnings of roughly US$178 million by 2029, but even they worry that heavy AI and tech spending could keep margins thin, which may look very different once this latest capital raise is fully reflected in their models.

Explore 3 other fair value estimates on MakeMyTrip - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your MakeMyTrip research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free MakeMyTrip research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MakeMyTrip's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.